OR WAIT null SECS
Headed to ACC.22 this weekend or following along virtually? Hear from Don't Miss a Beat co-hosts Drs. Vaduganathan and Greene on their top picks from the late-breaking sessions at the upcoming American College of Cardiology meeting.
Every year, the American College of Cardiology (ACC) annual meeting serves as the premier showcase for advancements and discussions around basic science and clinical application of cardiovascular medicine.
This year, the conference not only represents this showcase of knowledge, but also a major turning point in the battle against COVID-19 as the largest in-person cardiology conference to occur since 2020. With these factors combined, ACC.22, which is being held in Washington D.C. and virtually from April 2-4, is expected to be a celebration of the cardiology community as well as the struggles and triumphs the field has had to endure in the past 2 years.
Headlining this celebration of cardiology will be the multiple late-breaking sessions at this year’s conference. With more than half a dozen sessions dedicated to late-breaking science, attendees are often forced to pick and choose between sessions and other activities on the conference floor. With this in mind, March’s episode of Don’t Miss a Beat is focused on providing listeners with a preview of the hosts' top picks from late-breaking science slated to be presented at ACC.22.
In the episode, co-hosts Muthiah Vaduganathan, MD, MPH, and Stephen Greene, MD, walk through their picks of top data through the lens of specialists in cardiorenal metabolic diseases. Their picks include SODIUM-HF, PROMPT-HF, SCORED, and DIAMOND. Before diving into their ACC.22 discussion, our hosts also take a moment to expound on the recent announcement from Boehringer Ingelheim and Eli Lilly and Company disclosing their intent to end the phase 3 EMPA-KIDNEY trial early based on the trial’s Independent Data Monitoring Committee’s recommendation.